Rosuvastatin – safety of use Review article
Article Sidebar
Published:
Sep 30, 2015
Keywords:
rosuvastatin, side effects, safety of use
Main Article Content
Abstract
The strongest hypolipidemic statin – rosuvastatin – is also a very safe drug, which has been shown by independent analyses of safety and tolerability, and incidence rate of therapy cessation with this drug, resulting from the occurrence of adverse events, is comparable with other statins. Hydrophilicity of molecule, small hepatic metabolism and absence of the drug metabolism by cytochrome P450 3A4 have influence on lower risk of drug interactions and side effects during therapy with rosuvastatin.
Article Details
How to Cite
Barylski , M. (2015). Rosuvastatin – safety of use. Medycyna Faktow (J EBM), 8(3(28), 24-27. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2292
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Barylski M., Filipiak K.J.: Rosuwastatyna. Biblioteka czasopisma Cardiology Journal. Via Medica, Gdańsk 2010.
2. McAfee A.T., Ming E.E., Seeger J.D. et al.: The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy. Pharmacoepidemiol. Drug Safety 2006; 15(7): 444-453.
3. Goettsch W.G., Heintjes E.M., Kastelein J.J.P. et al.: Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. Pharmacoepidemiol. Drug Safety 2006; 15(7): 435-443.
4. Brewer H.B.: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 2003; 92(Supl.): 23K-29K.
5. Nicholls S.J., Ballantyne C.M., Barter P.J. et al.: Effect of the intensive statin regiments on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
6. Abe M., Maruyama N., Okada K. et al.: Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J. Atheroscler. Thromb. 2011; 18: 1018-1028.
7. Stein E.A., Vidt D.G., Shepherd J. et al.: Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis 2012; 221: 471-477.
8. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.
9. de Zeeuw D., Anzalone D.A., Cain V.A. et al.: Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3(3): 181-190.
10. Filipiak K.J., Kapłon-Cieślicka A., Opolski G.: Interakcje lekowe statyn. W: Aktualny stan wiedzy na temat statyn. Banach M., Filipiak K.J., Opolski G. (red.). Termedia, Poznań 2013: 403-424.
11. Pinheiro L.F., França C.N., Izar M.C. et al.: Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. Int. J. Cardiol. 2012; 156(1): 125-129.
2. McAfee A.T., Ming E.E., Seeger J.D. et al.: The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy. Pharmacoepidemiol. Drug Safety 2006; 15(7): 444-453.
3. Goettsch W.G., Heintjes E.M., Kastelein J.J.P. et al.: Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. Pharmacoepidemiol. Drug Safety 2006; 15(7): 435-443.
4. Brewer H.B.: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 2003; 92(Supl.): 23K-29K.
5. Nicholls S.J., Ballantyne C.M., Barter P.J. et al.: Effect of the intensive statin regiments on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
6. Abe M., Maruyama N., Okada K. et al.: Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J. Atheroscler. Thromb. 2011; 18: 1018-1028.
7. Stein E.A., Vidt D.G., Shepherd J. et al.: Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis 2012; 221: 471-477.
8. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.
9. de Zeeuw D., Anzalone D.A., Cain V.A. et al.: Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3(3): 181-190.
10. Filipiak K.J., Kapłon-Cieślicka A., Opolski G.: Interakcje lekowe statyn. W: Aktualny stan wiedzy na temat statyn. Banach M., Filipiak K.J., Opolski G. (red.). Termedia, Poznań 2013: 403-424.
11. Pinheiro L.F., França C.N., Izar M.C. et al.: Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. Int. J. Cardiol. 2012; 156(1): 125-129.